



Corrigendum

Corrigendum to “Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181” [The Journal of Prevention of Alzheimer's Disease (2026) 100664]

Moeko Noguchi-Shinohara, Daiki Muramatsu, Ayano Shima, Yasuhiro Sakashita, Yasutake Tada, Hiroki Yamaguchi, Junji Komatsu, Tokuhei Ikeda, Kenjiro Ono *

Department of Neurology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa 920-8640, Japan

The authors regret that the patient number values in Figs. 2A and 2B, and the values in Supplementary Tables 2 and 3 were incorrect and have been corrected to the correct values. The p-values on page 3 of the text that relate to Supplementary Tables 2 and 3 have been correctly revised,

and the following sentence “Although the differences did not reach statistical significance, women had a more than 2-fold higher discontinuation rate than men and non-carriers, respectively (Supplementary Table 3)” has been deleted.

DOI of original article: <https://doi.org/10.1016/j.tjpad.2026.100664>.


* Corresponding author.

E-mail address: onoken@med.kanazawa-u.ac.jp (K. Ono).

<https://doi.org/10.1016/j.tjpad.2026.100668>

Available online 15 September 2026

2274-5807/© 2026 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



The authors would like to apologise for any inconvenience caused. the online version, at [doi:10.1016/j.tjpad.2026.100668](https://doi.org/10.1016/j.tjpad.2026.100668).

Supplementary materials

Supplementary material associated with this article can be found, in